Environmental exposures are important risk factors for advanced liver fibrosis in African American adults.

ALD, alcohol-associated liver disease ALT, alanine aminotransferase APC, annual percent change Aetiology BMI, body mass index CI, confidence interval Environmental toxins FIB-4, Fibrosis-4 HBV, hepatitis B virus HCV, hepatitis C virus HR, hazard ratio KI, kidney insufficiency LF, liver fibrosis MA, Mexican American NAFLD, non-alcoholic fatty liver disease NEI, no exposure identified NHANES, National Health and Nutrition Evaluation Survey NHB, non-Hispanic Black NHW, non-Hispanic White Non-invasive scores O, other race PCB, polychlorinated biphenyl Q1–Q4, quartiles 1–4 Racial disparities Screening ULN, upper limit of normal USFLI, US Fatty Liver Index VH, viral hepatitis WC, waist circumference

Journal

JHEP reports : innovation in hepatology
ISSN: 2589-5559
Titre abrégé: JHEP Rep
Pays: Netherlands
ID NLM: 101761237

Informations de publication

Date de publication:
Apr 2023
Historique:
received: 20 10 2022
revised: 10 01 2023
accepted: 21 01 2023
entrez: 20 3 2023
pubmed: 21 3 2023
medline: 21 3 2023
Statut: epublish

Résumé

The prevalence and aetiology of liver fibrosis vary over time and impact racial/ethnic groups unevenly. This study measured time trends and identified factors associated with advanced liver fibrosis in the United States. Standardised methods were used to analyse data on 47,422 participants (≥20 years old) in the National Health and Nutrition Examination Survey (1999-2018). Advanced liver fibrosis was defined as Fibrosis-4 ≥2.67 and/or Forns index ≥6.9 and elevated alanine aminotransferase. The estimated number of people with advanced liver fibrosis increased from 1.3 million (95% CI 0.8-1.9) to 3.5 million (95% CI 2.8-4.2), a nearly threefold increase. Prevalence was higher in non-Hispanic Black and Mexican American persons than in non-Hispanic White persons. In multivariable logistic regression analysis, cadmium was an independent risk factor in all racial/ethnic groups. Smoking and current excessive alcohol use were risk factors in most. Importantly, compared with non-Hispanic White persons, non-Hispanic Black persons had a distinctive set of risk factors that included poverty (odds ratio [OR] 2.09; 95% CI 1.44-3.03) and susceptibility to lead exposure (OR 3.25; 95% CI 1.95-5.43) but did not include diabetes (OR 0.88; 95% CI 0.61-1.27; The number of people with advanced liver fibrosis has increased, creating a need to expand the liver care workforce. The risk factors for advanced fibrosis vary by race/ethnicity. These differences provide useful information for designing screening programmes. Poverty and toxic exposures were associated with the high prevalence of advanced liver fibrosis in non-Hispanic Black persons and need to be addressed. Because liver disease often produces few warning signs, simple and inexpensive screening tests that can be performed by non-specialists are needed to allow timely diagnosis and linkage to care. This study shows that non-Hispanic Black persons have a distinctive set of risk factors that need to be taken into account when designing liver disease screening programs. Exposure to exogenous toxins may be especially important risk factors for advanced liver fibrosis in non-Hispanic Black persons.

Sections du résumé

Background & Aims UNASSIGNED
The prevalence and aetiology of liver fibrosis vary over time and impact racial/ethnic groups unevenly. This study measured time trends and identified factors associated with advanced liver fibrosis in the United States.
Methods UNASSIGNED
Standardised methods were used to analyse data on 47,422 participants (≥20 years old) in the National Health and Nutrition Examination Survey (1999-2018). Advanced liver fibrosis was defined as Fibrosis-4 ≥2.67 and/or Forns index ≥6.9 and elevated alanine aminotransferase.
Results UNASSIGNED
The estimated number of people with advanced liver fibrosis increased from 1.3 million (95% CI 0.8-1.9) to 3.5 million (95% CI 2.8-4.2), a nearly threefold increase. Prevalence was higher in non-Hispanic Black and Mexican American persons than in non-Hispanic White persons. In multivariable logistic regression analysis, cadmium was an independent risk factor in all racial/ethnic groups. Smoking and current excessive alcohol use were risk factors in most. Importantly, compared with non-Hispanic White persons, non-Hispanic Black persons had a distinctive set of risk factors that included poverty (odds ratio [OR] 2.09; 95% CI 1.44-3.03) and susceptibility to lead exposure (OR 3.25; 95% CI 1.95-5.43) but did not include diabetes (OR 0.88; 95% CI 0.61-1.27;
Conclusions UNASSIGNED
The number of people with advanced liver fibrosis has increased, creating a need to expand the liver care workforce. The risk factors for advanced fibrosis vary by race/ethnicity. These differences provide useful information for designing screening programmes. Poverty and toxic exposures were associated with the high prevalence of advanced liver fibrosis in non-Hispanic Black persons and need to be addressed.
Impact and Implications UNASSIGNED
Because liver disease often produces few warning signs, simple and inexpensive screening tests that can be performed by non-specialists are needed to allow timely diagnosis and linkage to care. This study shows that non-Hispanic Black persons have a distinctive set of risk factors that need to be taken into account when designing liver disease screening programs. Exposure to exogenous toxins may be especially important risk factors for advanced liver fibrosis in non-Hispanic Black persons.

Identifiants

pubmed: 36937989
doi: 10.1016/j.jhepr.2023.100696
pii: S2589-5559(23)00027-7
pmc: PMC10017423
doi:

Types de publication

Journal Article

Langues

eng

Pagination

100696

Subventions

Organisme : NIAAA NIH HHS
ID : R01 AA024762
Pays : United States

Informations de copyright

© 2023 The Author(s).

Déclaration de conflit d'intérêts

All authors declare no relevant or material financial interests that relate to the research described in this paper. Please refer to the accompanying ICMJE disclosure forms for further details.

Références

Radiol Imaging Cancer. 2020 Aug 21;2(5):e200107
pubmed: 33778737
Ann Hepatol. 2020 Jul - Aug;19(4):404-410
pubmed: 32376236
J Hepatol. 2019 Jan;70(1):151-171
pubmed: 30266282
N Engl J Med. 2021 Nov 4;385(19):1737-1749
pubmed: 34554658
Int J Obes (Lond). 2018 Apr;42(4):926-929
pubmed: 29437160
Aliment Pharmacol Ther. 2015 Jan;41(1):65-76
pubmed: 25376360
J Gastrointest Surg. 2013 Jul;17(7):1265-73
pubmed: 23636881
J Am Heart Assoc. 2018 Jul 14;7(14):
pubmed: 30007934
Environ Health Perspect. 2010 Dec;118(12):1735-42
pubmed: 21126940
Cancer. 2021 May 1;127(9):1395-1406
pubmed: 33629759
Eur J Gastroenterol Hepatol. 2021 Mar 1;33(3):388-398
pubmed: 32317586
JAMA. 2019 Dec 24;322(24):2389-2398
pubmed: 31860047
Hepatol Commun. 2022 Jan;6(1):8-11
pubmed: 34558225
JAMA. 2020 Jun 23;323(24):2526-2528
pubmed: 32573660
NCHS Data Brief. 2020 Feb;(360):1-8
pubmed: 32487284
Future Oncol. 2021 Aug;17(24):3271-3280
pubmed: 34047192
Stat Med. 2000 Feb 15;19(3):335-51
pubmed: 10649300
Hepatology. 2019 Mar;69(3):1064-1074
pubmed: 30014489
PLoS One. 2016 Mar 07;11(3):e0150978
pubmed: 26950933
Proc Natl Acad Sci U S A. 2021 Feb 2;118(5):
pubmed: 33446511
Gastroenterology. 2020 Jan;158(1):200-214
pubmed: 31563624
Vital Health Stat 2. 2013 Sep;(161):1-24
pubmed: 25090154
Gastroenterology. 2021 Nov;161(5):1657-1669
pubmed: 34602251
J Hepatol. 2021 Sep;75(3):659-689
pubmed: 34166721
Hepatology. 2019 Mar;69(3):1020-1031
pubmed: 30398671
Eur J Gastroenterol Hepatol. 2018 Apr;30(4):404-410
pubmed: 29215435
Am J Gastroenterol. 2020 Jan;115(1):96-104
pubmed: 31517639
PLoS One. 2021 Nov 30;16(11):e0260320
pubmed: 34847156
Nat Commun. 2022 Mar 10;13(1):1259
pubmed: 35273160
Eur J Clin Nutr. 2007 Dec;61(12):1373-9
pubmed: 17299478
Cell. 2020 Oct 29;183(3):684-701.e14
pubmed: 33058756
Hypertension. 2018 Sep;72(3):602-609
pubmed: 30354757
Hepatology. 2023 Jan 1;77(1):256-267
pubmed: 35477908
Health Psychol. 2016 Sep;35(9):987-95
pubmed: 27175576
Ann N Y Acad Sci. 2008;1136:276-88
pubmed: 18579887
J Clin Gastroenterol. 2015 Sep;49(8):690-6
pubmed: 25291348
Hepatology. 2017 Jul;66(1):84-95
pubmed: 28195363
Liver Int. 2023 Jan;43(1):170-179
pubmed: 35567761
Am J Prev Med. 2016 Aug;51(2):206-215
pubmed: 27178884
Am J Gastroenterol. 2017 May;112(5):740-751
pubmed: 27725647
NPJ Genom Med. 2016;1:
pubmed: 27398227
MedGenMed. 2007 May 03;9(2):26
pubmed: 17955082
Hepatology. 2020 Nov;72(5):1605-1616
pubmed: 32043613
J Clin Epidemiol. 1996 Dec;49(12):1373-9
pubmed: 8970487
Hepatology. 2006 Jun;43(6):1317-25
pubmed: 16729309

Auteurs

Ning Ma (N)

Division of Liver Diseases, Icahn School of Medicine Mount Sinai, New York, NY, USA.

Rowena Yip (R)

Department of Diagnostic, Molecular and Interventional Radiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Sara Lewis (S)

Department of Diagnostic, Molecular and Interventional Radiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Amreen Dinani (A)

Division of Liver Diseases, Icahn School of Medicine Mount Sinai, New York, NY, USA.

Christina Wyatt (C)

Department of Medicine, Division of Nephrology, Duke University School of Medicine, Durham, NC, USA.

Michael Crane (M)

Department of Environmental Medicine and Public Health, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Artit Jirapatnakul (A)

Department of Diagnostic, Molecular and Interventional Radiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Li Li (L)

Division of Liver Diseases, Icahn School of Medicine Mount Sinai, New York, NY, USA.

Costica Aloman (C)

Department of Medicine, Rush University Medical Center, Chicago, IL, USA.

Meena B Bansal (MB)

Division of Liver Diseases, Icahn School of Medicine Mount Sinai, New York, NY, USA.

Douglas Dieterich (D)

Division of Liver Diseases, Icahn School of Medicine Mount Sinai, New York, NY, USA.

Brooke Wyatt (B)

Division of Liver Diseases, Icahn School of Medicine Mount Sinai, New York, NY, USA.

David Yankelevitz (D)

Department of Diagnostic, Molecular and Interventional Radiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Claudia Henschke (C)

Department of Diagnostic, Molecular and Interventional Radiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Andrea D Branch (AD)

Division of Liver Diseases, Icahn School of Medicine Mount Sinai, New York, NY, USA.

Classifications MeSH